このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

メタボリックシンドロームに対する褐色脂肪組織媒介効果のための慢性風邪および栄養補助食品によって増強された褐色脂肪活性化および褐変効率(BEACON BEAMS研究)

2026年11月5日 更新者:Melvin Leow、Institute for Human Development and Potential (IHDP), Singapore

Our body fat (adipose tissue) is largely made up of white adipose tissue (WAT) that stores surplus energy as white fat depots. In addition, adult humans have another type of fat similar to the brown fat in babies that burns up fat to generate heat for maintenance of body temperature during cold exposure. Adults have much lesser amounts of such brown adipose tissue (BAT), most of which are located within the sides of the neck and under the skin above the collar bones as well as along the sides of the spine. BAT consists of both classical brown fat identical to that found in babies as well as beige fat (composed of brown-in-white or 'brite' fat cells) found mainly in adults. Both types of BAT burn fat upon activation by various stimuli such as cold or by substances like curcumin found in turmeric ginger rhizome root.

This study is carried out to find out the effects of cold stimulation and/or a known BAT-activating nutraceutical among those overweight/obese people suffering from metabolic syndrome.

調査の概要

状態

積極的、募集していない

条件

介入・治療

詳細な説明

This study will recruit 60 participants that are overweight/obese people suffering from metabolic syndrome. The participants will be asked to come to the Clinical Nutrition Research Centre (CNRC) for a screening session (1st visit) and given plenty of time to read this information sheet and the opportunity to ask questions. Once the participants are fully informed regarding the study and all their questions have been satisfactorily answered, the participants will be given a consent form to complete and sign in the presence of the researcher. Following this, in order to gauge their suitability for taking part in the study, an assessment will be carried out. This assessment needs to be carried out in a fasted state and participants would therefore have to come one morning following an overnight fast. The screening will include anthropometric measurements, blood pressure measurement and blood sampling. Anthropometric measurements taken will be height, weight, waist circumference and hip circumference. Body composition will be measured using an electrical impedance analyser (BIA). Blood pressure will be measured using an automatic blood pressure monitor. The participants will also undergo a blood sampling from their vein (6 mL or approximately 1.5 teaspoons) to be tested for thyroid function, glucose and lipid profile. Pre-menopausal females will also undergo a urine pregnancy test to exclude pregnancy prior to participation at study entry. The participants who have been accepted into the study will be randomly assigned to one of the 3 parallel intervention groups below (20 subjects per group) via an online randomizer (www.randomizer.org). Randomization means assigning them to one of the three groups by chance, like tossing a coin or rolling a dice. The 3 parallel intervention groups (Week 0 to 12) are Group 1 (CS): Cold stimulation using cooling vest x 60 min once daily over 3 months, Group 2 (BN): Browning nutraceutical (2000mg curcumin) to be taken once daily over 3 months, Group 3 (CSBN): Cold stimulation using cooling vest x 60 min once daily and Browning nutraceutical (2000mg curcumin) to be taken once daily over 3 months. The participants will then be expected to come to the centre for a total of six separate test sessions, over a span of 6 months (2 test sessions each at week 0, 12 and 24 approximately +/-2 weeks). For each of the six test sessions,the participants will be required to fast overnight and avoid caffeine and alcohol for 8-10 hours, only plain water can be consumed during the fast before reporting at the CNRC in the morning between 8 to 9 am. The participants are to avoid any physical activity/exercise and alcohol on the day prior to the visit. The test sessions will be as follows: On the 2nd visit (first test session) at week 0, the participants will need come to CNRC in the morning and a fasting blood sample (40 mL or approximately 8 teaspoons) and urine sample will be collected before they undergo metabolic rate measurement with IRT focusing on their neck and area above the collar bone in a whole body room calorimeter for the next 45 minutes. The participants will then undergo a mild cold stimulation of about 14 degree Celsius by wearing a cooling vest for the next 45 minutes, in which metabolic rate measurement and IRT in the whole body calorimeter will be performed during this period. Please note that wearing the cooling vest may lead to some shivering, but it is generally considered safe. Upon exiting the whole body calorimeter, the participants will remove the cooling vest and then proceed to Clinical Imaging Research Centre (CIRC) located at the basement level of the same building, where an intravenous indwelling cannula will be inserted into an arm vein and 20 mL (approximately 4 teaspoons) of blood and another urine sample will be collected again. The participants will then wear the cooling vest again for approximately another 60 min and in between they will receive an intravenous injection of a radioactive labeled glucose called 18-FDG through the intravenous cannula. The cooling vest will be removed just prior to the start of the PET (Positron Emission Tomography) and MRI/MRS (Magnetic Resonance Imaging/Magnetic Resonance Spectroscopy) that will take place over the next 1 hour to quantify BAT (Brown Adipose Tissue) and abdominal white fat including liver and muscle fat. The participants will also need to undergo a body composition evaluation using dual energy X-ray absorptiometry (DXA) (approximately 20 mins duration) which allows quantification of fat, lean and bone mass. However, the participants will be given the option to do the DXA scan on their next/3rd visit according to their preference. After which, the participants will be free to leave. On the 3rd visit (second test session) at week 0, the participants will need come to CNRC in the morning for an Oral Glucose Tolerance Test (OGTT). Anthropometric measurements taken will be height, weight, waist circumference and hip circumference. Body composition will be measured using an electrical impedance analyser (BIA). Blood pressure will be measured using an automatic blood pressure monitor. A fasting blood sample (4 mL or less than 1 teaspoon) will be collected and participants will then be required to consume a glucose drink (75g of glucose) within 5 minutes. Subsequently after 120 min, another blood sample (4 mL or less than 1 teaspoon) will be collected. During the entire test session, the participants will have to stay rested and in the laboratory. Television and a workspace will be provided for the participants use if required. At the end of 2 hours of testing, for participants who have not undergone for the DXA scan on the 2nd visit, they will then proceed to complete the DXA scan (approximately 20 mins duration). After which, participants will be free to leave.The above 2 test sessions may be scheduled in any order,but to be completed no more than 2 weeks apart. The participants will now start the study intervention procedures as per the intervention group randomly assigned to them for the next 12 weeks or 3 months. Participants who are assigned to group 1 / cold stimulation (CS), will be expected to undergo a mild cold stimulation of about 14 degree Celsius by wearing a cooling vest for approximately an hour daily for the next 12 weeks or 3 months. Participants who are assigned to group 2 / browning nutraceutical (BN), will be expected to consume 2000mg of curcumin (in forms of capsules) daily for the next 12 weeks or 3 months. Curcumin is a naturally-occurring polyphenol antioxidant that is found in turmeric ginger rhizome root and has been widely known in Asia to have health benefits. Since both substances are commonly consumed among Asians, it is relevant to study their combined chronic clinical effects on BAT. Use of curcumin to stimulate BAT is essentially safe as both are naturally occurring plant derived substances from Curcuma longa rhizome. It is generally recognised as safe for human consumption. The US FDA has approved curcumin as 'Generally Recognised as Safe' (GRAS) status and allows these to be taken as foods ingredients. Participants who are assigned to group 3 / cold stimulation and browning nutraceutical (CSBN), will be expected to undergo a mild cold stimulation of about 14 degree Celsius by wearing a cooling vest for approximately an hour and, consume 2000mg of curcumin (in forms of capsules) daily for the next 12 weeks or 3 months. The participants will then be required to come for the 4th visit (third test session) and 5th visit (fourth test session) at week 12 (after completing the 3 months of intervention), as per follows:

On the 4th visit (third test session) at week 12, participants will repeat the same procedures as per that of the 2nd visit (first test session). For the 5th visit (fourth test session) at week 12, participants will need to come to CNRC in the morning in a fasted state and proceed first to CIRC for a 30 min MRI/ MRS only scan of BAT/WAT to study the fat composition. Subsequent procedures will be same as that of the 3rd visit (second test session). After which, there will be no more intervention and participants will continue with their usual lifestyle and diet for the next 3 months (week 12 to 24).The participants will lastly be required to come for the 6th visit (fifth test session) and 7th visit (sixth test session) at week 24 (6 months from start of study), and repeat the same procedures as per that of the 2nd visit (first test session) and the 3rd visit (second test session) respectively. Notes: *The 2 test sessions each at week 0, 12 and 24 may be scheduled within 4 weeks from each time point. *The following test sessions will be scheduled no more than 4 weeks apart: o First and second test sessions for Week 0 (in any order) o Third and fourth test sessions for Week 12 (in any order) o Fifth and sixth test sessions for Week 24 (in any order)

研究の種類

介入

入学 (推定)

60

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Singapore、シンガポール、117609
        • Singapore Institute of Clinical Sciences

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

21年~50年 (大人)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Male or Female

  • Chinese, Malay or Indian ethnicity

  • Age between 21 to 50 years

  • Able to give informed consent

  • Body mass index (BMI) between 23 to 32 kg/m2

  • Thyroid function test must be within the normal ranges

  • Willing to avail yourself for the whole study and follow study procedures

  • EITHER deemed to have pre-metabolic syndrome when waist circumference is > 90 cm in men or > 80 cm in women, with none or up to one of the following condition:

    • Triglyceride level ≥ 1.7 mmol/L
    • HDL cholesterol ≤ 1.0 mmol/L in men, and ≤ 1.3 mmol/L in women
    • Blood pressure ≥ 130/85 mmHg
    • Fasting blood glucose of ≥ 6.1 mmol/L
  • OR deemed to have metabolic syndrome when three or more of the following conditions are present:

    • Waist circumference > 90 cm in men and > 80 cm in women
    • Triglyceride level ≥ 1.7 mmol/L
    • HDL cholesterol ≤ 1.0 mmol/L in men, and ≤ 1.3 mmol/L in women
    • Blood pressure ≥ 130/85 mmHg
    • Fasting blood glucose of ≥ 6.1 mmol/L

Exclusion Criteria:

  • Are pregnant or contemplating pregnancy (for female subjects)
  • Partake in sports at the competitive and/or endurance levels
  • Have known glucose-6-phosphate dehydrogenase (G6PD) deficiency
  • Have major chronic disease such as heart disease or cancer
  • Take insulin or drugs known to affect glucose metabolism
  • Intentionally restrict food intake
  • Have major medical or surgical event requiring hospitalization within the preceding 3 months
  • Have taken antibiotics for 3 months before the study period
  • Are a smoker
  • Are an overnight shift worker
  • Have any known food allergy (eg. anaphylaxis to peanuts)
  • Having active Tuberculosis (TB) or currently receiving treatment for TB
  • Have any known Chronic Infection or known to suffer from or have previously suffered from or is a carrier of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV)
  • Are a member of the research team or their immediate family members. Immediate family member is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.
  • Enrolled in a concurrent research study judged not to be scientifically or medically compatible with the study of the CNRC
  • Have poor veins impeding venous access
  • Have any history of severe vasovagal syncope (blackouts or near faints) following blood draws
  • History of surgery with metallic clips, staples or stents
  • Presence of cardiac pacemaker or other foreign body in any part of the body
  • History of claustrophobia particularly in a MRI scanner

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:他の
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Cold Stimulation (CS)

Subjects will undergo a mild cold stimulation of about 14 degrees Celsius by wearing a cooling vest for approximately an hour daily for the next 12 weeks or 3 months.

Subject wear cooling vest to stay cool

実験的:Browning Nutraceutical (BN)

Subjects will consume 2000mg of curcumin daily for the next 12 weeks or 3 months.

Subject will consume 2000mg of curcumin a naturally-occurring polyphenol antioxidant that is found in turmeric ginger rhizome root

実験的:Cold Stimulation and Browning Nutraceutical (CSBN)

Subjects will undergo a mild cold stimulation of about 14 degrees Celsius by wearing a cooling vest for approximately an hour and consume 2000mg of curcumin daily for the next 12 weeks or 3 months.

Subject wear a cooling vest and consume 2000mg of curcumin

この研究は何を測定していますか?

主要な結果の測定

結果測定
時間枠
18-FDG-PET/MRIを用いたイメージングによる褐色脂肪組織活性化検出の変化。
時間枠:寒冷刺激の 0、12、24 週目
寒冷刺激の 0、12、24 週目
赤外線を用いたイメージングによる褐色脂肪組織活性化検出の変化
時間枠:寒冷刺激の 0、12、24 週目
寒冷刺激の 0、12、24 週目
全身熱量計を使用したエネルギー消費の変化。
時間枠:寒冷刺激の 0、12、24 週目
寒冷刺激の 0、12、24 週目
18-FDG-PET/MRIを用いたイメージングによる褐色脂肪組織活性化検出の変化。
時間枠:クルクミン摂取の 0、12、24 週目
クルクミン摂取の 0、12、24 週目
赤外線を用いたイメージングによる褐色脂肪組織活性化検出の変化
時間枠:クルクミン摂取の 0、12、24 週目
クルクミン摂取の 0、12、24 週目
全身熱量計を使用したエネルギー消費の変化。
時間枠:クルクミン摂取の 0、12、24 週目
クルクミン摂取の 0、12、24 週目
18-FDG-PET/MRIを用いたイメージングによる褐色脂肪組織活性化検出の変化。
時間枠:0週目、12週目、24週目の寒冷刺激とクルクミン摂取
0週目、12週目、24週目の寒冷刺激とクルクミン摂取
赤外線を用いたイメージングによる褐色脂肪組織活性化検出の変化
時間枠:0週目、12週目、24週目の寒冷刺激とクルクミン摂取
0週目、12週目、24週目の寒冷刺激とクルクミン摂取
全身熱量計を使用したエネルギー消費の変化。
時間枠:0週目、12週目、24週目の寒冷刺激とクルクミン摂取
0週目、12週目、24週目の寒冷刺激とクルクミン摂取

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2021年1月15日

一次修了 (実際)

2023年10月31日

研究の完了 (推定)

2028年8月16日

試験登録日

最初に提出

2020年10月14日

QC基準を満たした最初の提出物

2020年10月17日

最初の投稿 (実際)

2020年10月20日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月10日

QC基準を満たした最後の更新が送信されました

2026年11月5日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 2018/00823
  • 2018 (米国 NIH グラント/契約)

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。